Ferreira Tássia Sell, Villalobos Wendy Roldán, Gmyterco Vanessa Cunningham, Fonseca Diogo Simões, de Farias Marconi Rodrigues
Department of Veterinary Medicine, School of Medicine and Life Sciences, Pontifícia Universidade Católica do Paraná, Curitiba, Paraná, Brazil.
Graduate Program in Rehabilitation Sciences and Physical-Functional Performance, Faculty of Physiotherapy, Universidade Federal de Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil.
Vet Dermatol. 2025 Apr;36(2):177-185. doi: 10.1111/vde.13327. Epub 2025 Feb 3.
Canine atopic dermatitis (cAD) is a chronic inflammatory and pruritic dermatopathy requiring a multimodal therapeutic approach.
To assess the effectiveness, safety and cost of oclacitinib and prednisolone treatment in dogs with AD.
Twenty-three client-owned dogs with cAD.
Dogs were randomly assigned to one of two groups: Group 1 received prednisolone (0.5 mg/kg every 24 h) for 7 days, then oclacitinib (0.5 mg/kg) and prednisolone (0.5 mg/kg), were administered alternately with a 1 day pause between each drug, for 7 additional weeks. Group 2 received oclacitinib (0.5 mg/kg every 12 h for 14 days, then every 24 h) for 8 weeks. Assessments included the Canine Atopic Dermatitis Extent and Severity Index, 4th iteration (CADESI-04) and pruritus Visual Analog Scale (PVAS) on Day (D)0, D7, D14, D30, D45 and D60.
Both groups showed significant CADESI and PVAS reductions on D7 (p < 0.001). From D14 to D60, mean scores remained stable compared to D7, with no significant differences between groups. Adverse events included two dogs with polyuria and polydipsia, and three with polyphagia in Group 1, all of which resolved by D14. In Group 2, one dog experienced polyphagia, and two had self-limiting vomiting. Three dogs in Group 1 and one dog in Group 2 had mild increases in liver enzyme concentrations.
The combined protocol was effective and safe for managing itch and inflammation over a 60 day period. It had a 73.3% lower cost compared to oclacitinib alone.
犬特应性皮炎（cAD）是一种慢性炎症性瘙痒性皮肤病，需要采取多模式治疗方法。
评估奥克拉替尼和泼尼松龙治疗犬特应性皮炎的有效性、安全性和成本。
23只客户拥有的患有cAD的犬只。
将犬只随机分为两组：第1组接受泼尼松龙（每24小时0.5mg/kg）治疗7天，然后交替给予奥克拉替尼（0.5mg/kg）和泼尼松龙（0.5mg/kg）（每种药物之间间隔1天），持续7周。第2组接受奥克拉替尼（第14天每12小时0.5mg/kg，然后每24小时）治疗8周。评估指标包括第4版犬特应性皮炎范围和严重程度指数（CADESI-04）以及瘙痒视觉模拟量表（PVAS），分别在第0天、第7天、第14天、第30天、第45天和第60天进行评估。
两组在第7天时CADESI和PVAS均显著降低（p<0.001）。从第14天到第60天，与第7天相比，平均得分保持稳定，两组之间无显著差异。不良事件包括第1组中有2只犬出现多尿和烦渴，3只犬出现多食，所有这些症状在第14天时均得到缓解。在第2组中，1只犬出现多食，2只犬出现自限性呕吐。第1组中有3只犬和第2组中有1只犬肝酶浓度轻度升高。
联合方案在60天内有效且安全地控制了瘙痒和炎症。与单独使用奥克拉替尼相比，成本降低了73.3%。
